Performance Analysis of Novel Nucleic Acid Detection Kit for Mycoplasma pneumoniae.

Respiratory tract infections brought on by Mycoplasma pneumoniae is a severe threat for youngster well being. It has been troublesome to forestall and management for a spread of causes; subsequently, well timed prognosis is especially necessary for remedy of sufferers.
At current, the speedy M pneumoniae take a look at kits primarily based on nucleic acid amplification have been commercialized and used as major diagnostic instruments for M pneumoniae an infection, however present kits are time-consuming, which is troublesome to fulfill the requirement for correct and speedy prognosis of M pneumoniae throughout epidemics.
Rapid and correct take a look at kits are urgently required to diagnose M pneumoniae an infection. In this text, we evaluated the efficiency of a novel nucleic acid detection equipment (A) for M pneumoniae from feasibility and sensitivity, and in contrast it with equipment B.
Results confirmed this equipment has the benefit of being speedy, delicate, and particular, which meets the calls for for the prognosis of M pneumoniae an infection in medical settings.

Development and Evaluation of AccuPower COVID-19 Multiplex Real-Time RT-PCR Kit and AccuPower SARS-CoV-2 Multiplex Real-Time RT-PCR Kit for SARS-CoV-2 Detection in Sputum, NPS/OPS, Saliva and Pooled Samples.

  • Rapid and correct detection of the extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is important for the profitable management of the present international COVID-19 pandemic.
  • The real-time reverse transcription polymerase chain response (Real-time RT-PCR) is probably the most broadly used detection method.
  • This analysis describes the event of two novel multiplex real-time RT-PCR kits, AccuPower® COVID-19 Multiplex Real-Time RT-PCR Kit (NCVM) particularly designed for use with the ExiStation™48 system (comprised of ExiPrep™48 Dx and Exicycler™96 by BIONEER, Korea) for pattern RNA extraction and PCR detection, and AccuPower® SARS-CoV-2 Multiplex Real-Time RT-PCR Kit (SCVM) designed to be appropriate with producers’ on-market PCR devices.
  • The restrict of detection (LoD) of NCVM was 120 copies/mL and the LoD of the SCVM was 2 copies/μL for each the Pan-sarbecovirus gene and the SARS-CoV-2 gene. The AccuPower® kits demonstrated excessive precision with no cross reactivity to different respiratory-related microorganisms.
  • The medical efficiency of AccuPower® kits was evaluated utilizing the next medical samples: sputum and nasopharyngeal/oropharyngeal swab (NPS/OPS) samples.
  • Overall settlement of the AccuPower® kits with a Food and Drug Administration (FDA) accredited emergency use licensed business equipment (STANDARD™ M nCoV Real-Time Detection equipment, SD BIOSENSOR, Korea) was above 95% (Cohen’s kappa coefficient ≥ 0.95), with a sensitivity of over 95%. The NPS/OPS specimen pooling experiment was performed to confirm the usability of AccuPower® kits on pooled samples and the outcomes confirmed higher than 90% settlement with particular person NPS/OPS samples.
  • The medical efficiency of AccuPower® kits with saliva samples was additionally in contrast with NPS/OPS samples and demonstrated over 95% settlement (Cohen’s kappa coefficient > 0.95).
  • This research reveals the BIONEER NCVM and SCVM assays are comparable with the present commonplace affirmation assay and are appropriate for efficient medical administration and management of SARS-CoV-2.

Leave a Comment

Your email address will not be published.

Scroll to Top